. Mapping of the site in Slac2-a responsible for the binding of the globular tail of myosin-Va. (A) Deletion mutants of Slac2-a. Slac2-a consists of four distinct domains: the N-terminal SHD (SHD1 = RBD27, two Cys-based Zn 2+ -finger motifs, and SHD2; black boxes) (Fukuda et al., 2001a; Fukuda, 2002a; Fukuda, 2002b; Kuroda et al., 2002a) , a myosin-Va-GT-binding site (MyoVa-GT; cross-hatched box), a myosin-Va-exon-F-binding site (MyoVa-F; gray box) Nagashima et al., 2002) and an actin-binding site (hatched box) Kuroda et al., 2003) . The solid lines represent the deletion constructs of T7-tagged Slac2-a. The myosin-Va-GT-binding activity or the myosin-Va-exon-F-binding activity of each mutant is indicated after its name (+ or -) (see Fig. 1B ). Bold lines indicate the minimal myosin-Va-GT-binding site of Slac2-a (amino acid residues 147-240), which is completely different from the myosin-Va-exon-F-binding site (shaded box) Nagashima et al., 2002) . The sequences at the bottom represent the myosin-Va-GT-binding site of human and mouse Slac2-a. Residues in the sequences that are conserved and similar are shown against a black background and a shaded background, respectively. The amino acid numbers are indicated at the right-hand side of each sequence. (B) Mapping of the site in Slac2-a responsible for the binding of the GT of myosin-Va. Purified T7-Slac2-a mutants coupled with anti-T7 tag antibody-conjugated agarose were incubated with COS-7 cell lysates containing FLAG-myosin-Va-GT, and proteins trapped with the beads were analyzed by immunoblotting with HRP-conjugated anti-FLAG tag antibody (1/10,000 dilution) (top panel; Blot, anti-FLAG; IP, anti-T7). The same blots were then stripped and reprobed with HRP-conjugated anti-T7 tag antibody (1/10,000 dilution) to ensure that the same amounts of T7-Slac2-a mutant proteins had been loaded (bottom panel; Blot, anti-T7; IP, anti-T7). Note that myosin-Va-GT bound amino acids 147-240 of Slac2-a, adjacent to the SHD. Although the apparent molecular mass of the T7-Slac2-a mutants almost corresponded to their calculated molecular weight, several additional bands with higher molecular mass were observed in Slac2-a-∆146/∆321 mutant (asterisks in lane 4). These bands were probably produced by certain post-translational modifications caused by the truncation of Slac2-a protein. One of the possible modifications is fatty-acylation, which often contributes to the formation of a SDS-insensitive oligomer on SDS-polyacrylamide gel (Fukuda et al., 2001b) . In addition, Slac2-a-∆400 and -∆240 mutants contained some degradation products (lanes 5 and 6). The positions of the molecular mass markers (×10 -3 ) are shown on the right. (C) Rab27A enhanced myosin-Va-GT binding to Slac2-a. The purified T7-Slac2-a coupled with the beads was incubated with recombinant FLAG-myosin-Va-GT in the presence and absence of HA-Rab27A. The positions of the molecular mass markers (×10 -3 ) are shown on the left. has the effect of dilute mutations on Slac2-a binding activity or on the GT-binding site in Slac2-a ever been determined.
In this study we determined the minimal essential binding site for the GT of myosin-Va in Slac2-a and discovered that missense mutations in the GT of myosin-Va observed in dilute mice (i.e. I1510N, M1513K and D1519G) impair binding to Slac2-a. We also found that expression of green fluorescence protein (GFP)-tagged Slac2-a lacking the myosin-Va-GTbinding site causes perinuclear aggregation of melanosomes in melan-a cells. The physiological importance of the GT of myosin-Va in melanosome transport is discussed on the basis of our findings.
Materials and Methods
Construction of deletion mutants of Slac2-a and myosin-Va Deletion mutants of Slac2-a (pEF-T7-Slac2-a-∆146/∆241, pEF-T7-Slac2-a-∆GT (∆153-235) and pEGFP-C1-Slac2-a-∆GT) and of myosin-Va (pEF-FLAG-myosin-Va-GT-∆Af6 and -myosin-Va-GTAf6) were essentially constructed by conventional PCR as described previously (Fukuda et al., 1994; Fukuda and Mikoshiba, 2000; Fukuda et al., 2001b) using the following oligonucleotides with restriction enzyme sites (underlined) or stop codons (in bold): 5′-CGGATCCG-GTGGAGGTGGATCTGAGCC-3′ (Slac2-a-∆146 primer; sense), 5′-GCACTAGTCAGGGCTCCAGAGAGGTGGTGT-3′ (Slac2-a-∆241 primer, antisense), 5′-CCAGAGAGGTGGTCTCAGATCCACCTC-CAC-3′ (Slac2-a-∆GT primer, antisense), 5′-CGGATCCCAGGTAG-TCAAACAGATGTTC-3′ (myosin-Va-Af6 5′ primer, sense) and 5′-TCACTTGATTAGCTCCGGGT-3′ (myosin-Va-GT-∆Af6 3′ primer, antisense). Other expression constructs (pEF-T7-Slac2-a deletion mutants, pEF-HA-Rab27A, pEF-FLAG-myosin-Va-F-GT (exon F + globular tail), pEF-FLAG-brain myosin-Va-tail, pEF-FLAG-MC myosin-Va-tail and pEF-FLAG-myosin-Va-GT) were prepared as described previously Fukuda, 2002b; .
Site-directed mutagenesis
Mutant myosin-Va plasmids carrying an Ile-to-Asn substitution at amino acid position 1510 (I1510N), M1513K, D1519G or S1650E were produced by two-step PCR techniques using the following mutagenic oligonucleotides with artificial SplI sites (or SpeI) (underlined) as described previously (Fukuda et al., 1995) : 5′-TCG-TACGCACATAAACAAGTTAT-3′ (I1510N primer), 5′-TCGTACG-CACTTAAACAAGA-3′ (M1513K primer), 5′-TGCGTACGACAT-GCTGGCTA-3′ (D1519G primer), 5′-TGCGTACGACATGCTG-ACTA-3′ (SplI primer), 5′-CTCACTAGTTCGTTTTCTGAGCC-3′ (S1650E primer 1) and 5′-ACTAGTGAGATCGCAGATGAGGG-3′ (S1650E primer 2). The mutant myosin-Va-GT fragments were subcloned into the pEF-FLAG-tag expression vector as described previously (Fukuda et al., 1999; Fukuda and Mikoshiba, 2000) .
Cell culture, transfections and immunocytochemistry Cells of a murine immortalized melanocyte cell line, melan-a cells (generous gift of Dorothy C. Bennett, St George's Hospital Medical School, London, UK and Katsuhiko Tsukamoto, University of Yamanashi, Yamanashi, Japan), were cultured on glass-bottom dishes (35 mm dish; MatTek, Ashland, MA) (Bennett et al., 1987; Kuroda et al., 2003) . Transfection of pEGFP-C1-Slac2-a-∆GT, pEGFP-C1-Slac2-a or a control vector (pEGFP-C1 alone) was achieved with FuGENE 6 (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions. Two days after transfection, cells were fixed in 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, stained with anti-Rab27A mouse monoclonal antibody (BD Transduction Laboratories, Lexington, KY) and antimyosin-Va rabbit polyclonal antibody , followed by anti-rabbit Aalexa Fluor 633 IgG and anti-mouse Aalexa Fluor 568 IgG (Molecular Probes, Eugene, OR), and then examined for fluorescence and by bright-field images with a confocal fluorescence microscope (Fluoview; Olympus, Tokyo, Japan) as described previously (Kuroda et al., 2003) . The pigment distribution of the transfected cells ('dispersed' = normal peripheral distribution of melanosomes shown in Fig. 6E or 'aggregated' = accumulation of Fig. 2 . Differential effects of ionic strength on the Slac2-a⋅myosin-Va complex according to whether exon F is present. COS-7 cell lysates containing FLAG-myosin-Va-GT (or FLAG-myosin-Va-F-GT) (A) or containing FLAG-brain myosin-Va-tail (or FLAG-MC myosin-Vatail) (B) were incubated with T7-Slac2-a beads in the presence of the concentrations of NaCl indicated. Proteins that bound to the beads were first analyzed with HRP-conjugated anti-FLAG tag antibody (Blot: anti-FLAG, top panels), and then with HRP-conjugated anti-T7 tag antibody (Blot: anti-T7, bottom panels). Note that the binding of the MC-type myosin-Va to Slac2-a was resistant to ionic strength (up to 750 mM NaCl) (lanes 5-8), whereas binding of brain myosin-Va to Slac2-a was highly sensitive to ionic strength (lanes 1-4). (C) Tail constructs of brain-type and MC-type myosin-Va used in this study. melanosomes in the perinuclear regions shown in Fig. 6J ) was evaluated as described previously Kuroda et al., 2003) . More than 50 cells transfected with GFP-Slac2-a mutants in one dish were counted for each construct, and the same experiments were independently repeated three times (n>150).
Miscellaneous procedures
Transfection of plasmids into COS-7 cells (7.5×10 5 cells/10 cm dish, the day before transfection) was performed as described previously (Fukuda et al., 2001b) . Proteins were solubilized at 4°C for 1 hour with a buffer containing 1% Triton X-100, 250 mM NaCl, 1 mM MgCl2, 50 mM HEPES-KOH, pH 7.2, 0.1 mM phenylmethylsulfonyl fluoride, 10 µM leupeptin and 10 µM pepstatin A. T7-Slac2-a mutants were immunoprecipitated with anti-T7 tag antibody-conjugated agarose (Novagen, Madison, WI) as described previously (Fukuda et al., 1999; Fukuda and Mikoshiba, 2000) . SDS-PAGE and immunoblotting analyses with horseradish peroxidase (HRP)-conjugated anti-FLAG tag (Sigma Chemical Co.; St Louis, MO), anti-HA tag (Roche Molecular Biochemicals) and anti-T7 tag antibodies (Novagen) were also performed as described previously (Fukuda et al., 1999; Fukuda and Mikoshiba, 2000) . The intensity of the bands on x-ray film or gels was quantified with Basic Quantifier Software (version 1.0) (BioImage) or Lane Analyzer (version 3.0) (ATTO, Tokyo, Japan) as described previously (Fukuda and Mikoshiba, 2000) . The protein concentration of Slac2-a (or myosin-Va-tail) in the SDSpolyacrylamide gel was then estimated using bovine serum albumin as a reference. The statistical analyses and curve fitting were performed with a GraphPad PRISM computer program (version 4.0). The blots and gels shown in this paper are representative of at least two or three independent experiments.
Results

Globular tail and exon F of myosin-Va bind distinct domains of Slac2-a/melanophilin
A systematic deletion analysis was performed as described previously to determine the minimal essential domain required for the binding of myosinVa-GT to Slac2-a. As shown in Fig. 1A ,B, myosin-Va-GT bound a previously uncharacterized region adjacent to SHD2 (amino acids 147-240; cross-hatched box in Fig. 1A) . By contrast, myosin-Va-F-GT (i.e. exon F) has been shown to bind the middle region of Slac2-a (amino acids 320-406; shaded box in Fig. 1A ) Nagashima et al., 2002; Kuroda et al., 2003) . Interestingly, twice the amount of myosin-Va-GT bound to Slac2-a⋅Rab27A-beads as bound to Slac2-a-beads alone (i.e. without Rab27A) (Fig. 1C, top panel, compare lanes 1 and 2) , suggesting that myosin-Va-GT preferentially interacts with the Rab27A⋅Slac2-a complex rather than with Slac2-a alone.
The interaction between Slac2-a and myosin-Va-GT was less stable (Fig. 2 ) and much weaker (Fig. 3) than the interaction between Slac2-a and myosin-Va-F-GT. As shown in Fig. 2A , the Slac2-a⋅myosin-Va-GT interaction was highly sensitive to ionic strength (mild concentrations of NaCl), whereas the Slac2-a⋅myosin-Va-F-GT (+ exon F) interaction was resistant to high NaCl concentrations (up to 750 mM NaCl) ( Fig. 2A,C) . Similar results were obtained when the entire tail domain of brain-type myosin-Va and MC-type myosin-Va were used (Fig.  2B ). Slac2-a was also found to bind the brain myosin-Va-tail Journal of Cell Science 117 (4) with much lower affinity than the MC myosin-Va-tail (top panels in Fig. 3A) . Because the dose-dependence curve of the MC myosin-Va-tail (open circles in Fig. 3B ) was almost saturated, we used the curve-fitting program to calculate the EC50 (myosin-Va-tail concentration at half maximal binding = 0.15) and Bmax values (0.74 µg). Interestingly, under the maximal binding conditions, one molecule of Slac2-a (0.25 µg; approximately 3.6 pmol) was estimated to bind approximately two molecules of MC myosin-Va-tail (0.74 µg; approximately 6.7 pmol), which is consistent with the fact that myosin-Va functions as a dimer (Fig. 2C) . The dose-dependence curve of brain myosin-Va-tail (closed circles in Fig. 3B) , however, was not saturated under our experimental conditions, and only 0.15 µg of brain myosin-Va-tail bound Slac2-a at the highest concentrations of myosin-Va-tail (lane 7 in the upper right panel), suggesting that Slac2-a binds brain myosin-Va with more than ten times lower affinity than it binds MC myosin-Va (Fig. 3B , closed and open circles, respectively). Consistent with these findings, brain-type myosin-Va has been shown not to bind Slac2-a after extensive washing of the myosin-Va-beads (Wu et al., 2002a; Wu et al., 2002b) .
Effect of dilute missense mutations in the GT of myosinVa on Slac2-a binding Because the GT of mouse class V myosins (myosin-Va, Vb and Vc) consists of two parts, a first part and a second part, which contains an Af6 homology domain (Zhao et al., 1996; Hock et al., 1998; Reck-Peterson et al., 2000; Rodriguez and Cheney, 2002 ) (see boxed in Fig. 4A ), we attempted to identify the -4) , whereas the S1650E mutation, which mimics a phosphorylated form, had no effect at all (lane 6). (D) Effect of dilute missense mutations on the interaction between T7-Slac2-a and FLAG-myosinVa-F-GT. Note that in the presence of an MC-specific exon (exon F) all the onepoint mutants bound Slac2-a, the same as the wild-type protein did. Purified T7-Slac2-a coupled with anti-T7 tag antibody-conjugated agarose was incubated with COS-7 cell lysates containing FLAGmyosin-Va mutants, and the proteins trapped with the beads were analyzed by immunoblotting with HRP-conjugated anti-FLAG tag antibody (1/10,000 dilution) (middle panels; Blot, anti-FLAG; IP, anti-T7). The same blots were then stripped and reprobed with HRP-conjugated anti-T7 tag antibody (1/10,000 dilution) to ensure that the same amounts of T7-Slac2-a proteins had been loaded (bottom panels; Blot, anti-T7; IP, anti-T7). Input means 1/80 volume of the reaction mixture (top panels). The positions of the molecular mass markers (×10 -3 ) are shown on the left. domain(s) responsible for binding to Slac2-a. As shown in Fig.  4B (middle panel), Slac2-a was found to bind the first part of GT (myosin-Va-GT-∆Af6) but not the Af6 homology domain (myosin-Va-GT-Af6). It should be noted that several missense mutations were found in the first part of the myosin-Va-GT in dilute mice (I1510N, M1513K and D1519G; asterisks in Fig.  4A ) (Huang et al., 1998) , as well as the Ca 2+ /calmodulindependent protein kinase II phosphorylation site (Ser-1650; # in Fig. 4A ) (Karcher et al., 2001 ), all of which are highly conserved among mouse class V myosins. Because the S1650E mutant of the mouse myosin-Va (mimics the phosphorylated form of myosin-Va) does not recruit to Xenopus egg melanosomes, phosphorylation of Ser-1650 is thought to be a crucial process in cargo recognition of, and detachment from, myosin-Va (Karcher et al., 2001) . Surprisingly, all of the missense mutations almost completely abolished the Slac2-a binding activity of the myosin-Va-GT, whereas the S1650E mutant, which mimics the phosphorylated form, had no significant effect on binding to Slac2-a (Fig. 4C, lanes 2-6 in middle panel) . The lack of effect of the S1650E mutation on binding to Slac2-a may be explained by the species difference or the presence of other myosin-Va-GT binding protein(s) in Xenopus eggs (El-Husseini and Vincent, 1999) . By contrast, in the presence of exon F, the myosin-Va-F-GT protein containing such missense mutations bound Slac2-a, the same as the wild-type protein (Fig. 4D, middle panel) .
Expression of GFP-Slac2-a-∆GT inhibits melanosome transport in melan-a cells
To investigate further the physiological significance of the myosin-Va-GT·Slac2-a interaction, we prepared a deletion mutant of Slac2-a lacking the myosin-Va-GT-binding site (named Slac2-a-∆GT) (Fig. 5A) . Because the mutant Slac2-a-∆GT protein still contained both the Rab27A-binding site (amino acids residues 1-146) and the myosin-Va-exon-Fbinding site (amino acid residues 320-406), the mutant protein formed a tripartite protein complex with HA-Rab27A and FLAG-MC myosin-Va-tail, the same as the wild-type protein (Fig. 5B , lane 5 at third and fourth panels), but it did not interact with FLAG-brain myosin-Va-tail (Fig. 5B , lane 2 at third panel). The mutant Slac2-a-∆GT bound the MC myosinVa-tail with lower affinity than the wild-type Slac2-a, probably because of the lack of myosin-Va-GT·Slac2-a interaction, but it completely lacked brain myosin-Va-tail binding activity (Fig.  3B, open squares and closed squares, respectively) .
If the myosin-Va-GT-binding site was essential for melanosome transport in vivo, expression of the Slac2-a-∆GT in melan-a cells should inhibit melanosome transport (Wu et al., 2002a; Strom et al., 2002) , the same as the Slac2-a(EA) mutant lacking the MC myosin-Va-binding site (Kuroda et al., 2003) . As expected, almost all of the cells expressing the Slac2-a-∆GT protein exhibited 'aggregated' melanosomes in their perinuclear region (Fig. 6J) (91.6±3.0% (mean±s.e.) cells exhibiting aggregated melanosomes, n=169). Slac2-a-∆GT-expressing cells exhibited segregation of endogenous Rab27A from myosin-Va (Fig. 6I , Rab27A in green and myosin-Va in red) and decreased immunoreactivity of endogenous myosinVa (compare panels C and H in Fig. 6 ). Similar attenuation of myosin-Va-immunoreactivity was observed in ashen-and leaden-mouse-derived melanocytes (Provance et al., 2002) as Journal of Cell Science 117 (4) Rab27A-binding, MC myosin-Va-tail-binding, and brain myosin-Va-tail-binding activity is indicated after their names (+ or -) (see Fig. 5B ). The amino acid numbers are indicated at both sides of each line. (B) Effect of deletion of the myosin-Va-GT-binding site of Slac2-a on formation of a tripartite protein complex (Rab27A·Slac2-a·myosin-Va). Purified T7-Slac2-a mutants coupled with anti-T7 tag antibodyconjugated agarose were incubated with COS-7 cell lysates containing HARab27A and FLAG-brain myosin-Va-tail or FLAG-MC myosin-Va-tail, and proteins trapped with the beads were analyzed by immunoblotting with HRPconjugated anti-FLAG tag antibody (1/10,000 dilution) (third panel; Blot: anti-FLAG, IP: anti-T7) and HRP-conjugated anti-HA tag antibody (1/10,000 dilution) (fourth panel; Blot: anti-HA, IP: anti-T7). The same blots were then stripped and reprobed with HRP-conjugated anti-T7 tag antibody (1/10,000 dilution) to ensure that the same amounts of T7-Slac2-a mutant proteins had been loaded (bottom panel; Blot: anti-T7, IP: anti-T7). Input means 1/80 volume of the reaction mixture (top and second panels). Note that the Slac2-a-∆GT mutant specifically impaired brain myosin-Va-tail binding activity (lanes 1 and 2), but that it normally interacted with Rab27A and MC myosin-Va-tail (lanes 4 and 5).
well as the Slac2-a(EA)-expressing melan-a cells (Kuroda et al., 2003) . By contrast, expression of the wild-type Slac2-a protein with the GFP tag ( Fig. 6A-E) or GFP alone had virtually no effect on melanosome transport (i.e. peripheral melanosome distribution), with both Rab27A and myosin-Va being present on the melanosomes (Fig. 6D , yellow) (12.1±3.3% or 4±2.6% cells exhibiting aggregated melanosomes, respectively).
Discussion
We and others previously showed that Slac2-a functions as a receptor for myosin-Va in melanocytes and that formation of a tripartite protein complex composed of Rab27A, Slac2-a and myosin-Va is essential for normal melanosome distribution Wu et al., 2002a; Strom et al., 2002; Kuroda et al., 2003) . In the present study we discovered two forms of myosin-Va binding to Slac2-a: weak interaction between GT and Slac2-a (amino acids 147-240) and a strong interaction between exon F and the middle region of Slac2-a (Fig. 1A) . The dilute missense mutations (I1510N, M1513K and D1519G) in the GT of myosin-Va impair only the former interaction, not the latter (Fig. 4) , indicating that the Slac2-a⋅myosin-Va-GT interaction should be physiologically relevant. The physiological significance of the latter interaction is evident on the basis of the following observations: (1) deletion of exon F by mutations in the alternative splicing sites causes the dilute phenotype (i.e. perinuclear aggregation of melanosomes) (Seperack et al., 1995; Huang et al., 1998) ; (2) expression of brain myosin-Va lacking an exon F cannot rescue the phenotype of dilute-derived melanocytes (Wu et al., 2002b) , and expression of MC myosin-Va-tail, but not of brain myosin-Va-tail, induces perinuclear aggregation of melanosomes (Wu et al., 2002b; da Silva Bizario et al., 2002; Westbroek et al., 2003) ; and (3) Slac2-a mutants lacking the exon-F-binding site cannot support normal melanosome distribution in melan-a cells (Kuroda et al., 2003) . We therefore concluded that both interaction sites in Slac2-a identified in this study, the myosin-Va-GT-binding site and the myosin-Vaexon-F-binding site, are essential for melanosome transport in melanocytes.
Do the GT and exon F of myosin-Va function differently, synergistically or sequentially in melanosome transport? Although a previous analysis of yeast myosin V mutants showed that the tail domain has two distinct functions (Catlett et al., 2000) , the GT and exon F of mammalian myosin-Va probably function synergistically in melanosome transport, given the following observations. First, neither the GT nor exon F alone (GST-myosin-Va-exon-F) recognized Slac2-a or melanosomes in melanocytes (data not shown) (Wu et al., 2002b) , indicating that both domains are required for recognition of melanosomes in vivo. Second, both the mutant Slac2-a lacking the myosin-Va-GT-binding site and the mutant lacking the exon-F-binding site failed to mediate melanosome transport (Fig. 6J) (Kuroda et al., 2003) . Third, the phenotype induced by expression of Slac2-a-∆GT or Slac2-a(EA) lacking exon-F-binding activity in melanocytes is identical, indicating that both sites function at the same step of melanosome Fig. 6 . Deletion of the myosin-Va-GT-binding site of Slac2-a creates a dilute-like phenotype in wild-type melanocytes. Melan-a cells were transfected with a vector encoding GFP-tagged wild-type Slac2-a (A-E) or mutant GFP-Slac2-a-∆GT (F-J). After the cells were fixed and permeabilized, they were stained with anti-Rab27A (green) and antimyosin-Va (red) antibodies followed by Alexa Fluor secondary antibody conjugates as described previously (Kuroda et al., 2002a; Kuroda et al., 2003) . The cells were examined for fluorescence of GFP-Slac2-a proteins (A and F), Rab27A (B and G) and myosin-Va (C and H) by confocal microscopy. Bright-field images (E and J) show the melanosome distribution in the cells, and the mutant GFPSlac2-a-∆GT-expressing cell is outlined in yellow (J). D and I are merged images of Rab27A and myosin-Va. Note that expression of GFP-Slac2-a-∆GT induced melanosome aggregation in the perinuclear region (J), segregation of myosin-Va from Rab27A (I) and attenuation of myosin-Va-immunoreactivity (H), whereas the wild-type Slac2-a-expressing cell exhibited peripheral melanosome distribution (E), with both Rab27A and myosin-Va being colocalized on melanosomes (D). Bars, 10 µm. transport ( Fig. 6J) (Kuroda et al., 2003) . Both mutants induced melanosome aggregation in the perinuclear region of the melanocytes (i.e. inhibition of the melanosome transition from microtubules to actin filaments rather than actin-based transport itself) (Fig. 6J ) and induced segregation of myosinVa from Rab27A (Fig. 6I ) and attenuation of myosin-Vaimmunoreactivity (Fig. 6H) . Because deletion of the GTbinding site of Slac2-a slightly reduced the binding affinity to MC myosin-Va (Fig. 3B) , we speculate that both the GT-and exon-F-binding sites of Slac2-a are essential for higher affinity or stable recognition of myosin-Va in vivo. Alternatively, the interaction between myosin-Va-GT and Slac2-a may be a prerequisite for starting unidirectional actin-based transport driven by the myosin-Va motor.
In summary, we have identified two distinct myosin-Vabinding sites in Slac2-a, the GT-binding site (amino acids 147-240) and the exon-F-binding site (amino acids 320-406), both of which are essential for melanosome transfer from microtubules to actin filaments. Because missense mutations in the GT of myosin-Va selectively impair the former interaction, the recognition mechanism of myosin-Va by Slac2-a is not so simple as previously thought. Three-dimensional structural analysis of the Slac2-a·MC myosin-Va complex will be necessary to fully understand the role of the tripartite protein complex in the melanosome transfer step at the molecular level.
